BidaskClub upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a strong sell rating to a sell rating in a research note published on Saturday.

A number of other research firms have also issued reports on TBPH. ValuEngine lowered Theravance Biopharma from a hold rating to a sell rating in a research note on Monday, October 2nd. Zacks Investment Research upgraded Theravance Biopharma from a sell rating to a hold rating and set a $37.00 price objective on the stock in a research note on Tuesday, October 10th. Cantor Fitzgerald reiterated a buy rating and set a $55.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, September 26th. Robert W. Baird reiterated a sell rating and set a $22.00 price objective on shares of Theravance Biopharma in a research note on Wednesday, November 1st. Finally, Needham & Company LLC reiterated a buy rating on shares of Theravance Biopharma in a research note on Tuesday, December 5th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Theravance Biopharma has an average rating of Hold and a consensus target price of $41.86.

Shares of Theravance Biopharma (NASDAQ TBPH) opened at $29.64 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 7.21 and a current ratio of 7.53. Theravance Biopharma has a one year low of $23.15 and a one year high of $43.44. The stock has a market capitalization of $1,600.00, a price-to-earnings ratio of -5.74 and a beta of 2.35.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.05). Theravance Biopharma had a negative net margin of 1,604.87% and a negative return on equity of 99.43%. research analysts anticipate that Theravance Biopharma will post -4.84 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its stake in Theravance Biopharma by 3.6% in the 2nd quarter. BlackRock Inc. now owns 3,638,838 shares of the biopharmaceutical company’s stock worth $144,972,000 after acquiring an additional 126,393 shares during the last quarter. Virtu KCG Holdings LLC bought a new position in Theravance Biopharma in the 2nd quarter worth about $742,000. Alps Advisors Inc. increased its stake in Theravance Biopharma by 10.3% in the 3rd quarter. Alps Advisors Inc. now owns 53,013 shares of the biopharmaceutical company’s stock worth $1,815,000 after acquiring an additional 4,944 shares during the last quarter. Northern Trust Corp increased its stake in Theravance Biopharma by 6.1% in the 2nd quarter. Northern Trust Corp now owns 530,049 shares of the biopharmaceutical company’s stock worth $21,117,000 after acquiring an additional 30,611 shares during the last quarter. Finally, New York State Common Retirement Fund increased its stake in Theravance Biopharma by 9.2% in the 2nd quarter. New York State Common Retirement Fund now owns 46,300 shares of the biopharmaceutical company’s stock worth $1,845,000 after acquiring an additional 3,899 shares during the last quarter. Institutional investors and hedge funds own 86.01% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Theravance Biopharma (TBPH) Rating Increased to Sell at BidaskClub” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://theolympiareport.com/2018/01/23/theravance-biopharma-tbph-rating-increased-to-sell-at-bidaskclub.html.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.